U.S. Chemicals Stock News

TG Therapeutics recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where CEO Michael S. Weiss outlined updates on the company and its multiple sclerosis therapy Briumvi. Investors are paying close attention to fresh commentary on Briumvi demand and management’s 2026 priorities, viewing this conference appearance as a key indicator of how the commercial story may be evolving. We’ll now examine how expectations around updated Briumvi demand commentary at...

Transocean (RIG) shares are in focus after the company disclosed new work for two offshore rigs, with contracts in Brazil and Norway adding approximately $168 million of firm backlog and extending visibility on future drilling activity. See our latest analysis for Transocean. The new rig awards arrive after a strong run in the share price. Transocean’s 90 day share price return of 36.86% contrasts with a more modest 0.71% year to date gain, while the 1 year total shareholder return of 4.40%...

Nurix Therapeutics recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with CEO Arthur T. Sands outlining the company’s latest developments to investors and industry participants. A subsequent wave of analyst upgrades and an overall Outperform consensus have put fresh attention on how the market evaluates Nurix’s prospects. Next, we will examine how this cluster of analyst upgrades shapes Nurix Therapeutics’ investment narrative in light of its recent...

If you are wondering whether 3M's current share price reflects its true worth, you are not alone. This article is built to help you size up what you are actually paying for. 3M's stock recently closed at US$167.94, with returns of 2.7% over 7 days, a 0.6% decline over 30 days, 3.8% year to date and 27.1% over 1 year, while the 3 year and 5 year figures sit at 73.4% and 45.9% respectively. Recent headlines around 3M have focused on its ongoing restructuring efforts and legal settlements, as...

RBC Bearings (RBC) has drawn fresh investor attention after earnings estimates were revised upward, along with a strong Zacks Rank that points to improving confidence in its Aerospace/Defense and Industrial operations. See our latest analysis for RBC Bearings. The recent upward revisions to earnings estimates sit alongside a share price of $488.31, with a 90-day share price return of 27.17% and a 1-year total shareholder return of 63.88%. This suggests momentum has been building as investors...

On January 8, 2026, Peoples Bancorp Inc. director Carol A. Schneeberger sold 1,000 shares under a pre-arranged Rule 10b5-1 trading plan, while DA Davidson initiated research coverage with a Buy rating, citing core earnings per share that exceeded its expectations. The mix of planned insider selling alongside fresh analyst coverage highlights how differing insider and external analyst actions can shape investor interpretation of Peoples Bancorp’s financial outlook. We’ll now examine how DA...

In early January 2026, Charter Communications completed two fixed-income offerings totaling US$3.00 billion in senior unsecured notes, issuing 7.375% notes due 2036 and 7.00% notes due 2033 at par under Regulation S and Rule 144A. These sizeable bond sales come as investors and commentators highlight Charter’s ongoing operational challenges, including subscriber losses and intensifying broadband and cable competition, raising questions about how its capital structure supports its long-term...

Illumina has recently appointed genomics veteran Eric D. Green, M.D., Ph.D., as Chief Medical Officer and launched its Illumina Connected Multiomics cloud platform to help researchers analyze complex multiomic and multimodal data at scale. Together, a high-profile genomics leader joining the executive team and a new multiomics software offering highlight Illumina’s push to deepen its role in precision medicine and clinical genomics workflows. We’ll now explore how the Connected Multiomics...

Recently, market commentary highlighted that regional and small-cap banks, including Huntington Bancshares, have endured a 500-basis-point rate shock while maintaining historically high capital ratios and currently trade at lower forward P/E ratios than larger money center peers. This has renewed investor attention on Huntington’s combination of sector resilience, comparatively faster expected growth, and higher yield profile within the regional banking space. We’ll now examine how this...

In recent months, Nu Holdings, the parent of Nubank, has reported continued expansion of its digital banking platform to well over one hundred million customers across Brazil, Mexico, and Colombia, alongside strong revenue and earnings growth from its viral referral model. An important insight is that Nu Holdings’ incremental sales have been highly profitable, with earnings per share growing much faster than revenues, while its shares exhibit strong technical momentum consistent with the...

In the fourth quarter of 2025, O'Keefe Stevens Advisory boosted its stake in Topgolf Callaway Brands by 821,039 shares, investing about US$8.66 million and lifting its holding to roughly 1.17 million shares, while Tapasya Fund exited after management did not complete a planned Topgolf–Callaway split by mid-2025. These opposing institutional moves highlight how some investors are focusing on management’s raised 2025 guidance and improving traffic and cost trends, while others are reacting to...

Coverage of the Minneapolis ICE shooting has put Fox (FOXA) in the spotlight as cable news viewership climbs, and investors are watching how this attention feeds into advertising revenue, margins, and the upcoming earnings report. See our latest analysis for Fox. Against this backdrop, Fox's share price has moved to US$73.94, with a 30-day share price return of 3.99% and a stronger 90-day share price return of 28.48%. The 1-year total shareholder return of 52.89% points to momentum that has...

Recently, Zacks highlighted Custom Truck One Source with a Zacks Rank #2 (Buy) and an A grade for value, pointing to attractive valuation metrics such as a favorable price‑to‑book ratio versus peers. This positive third‑party assessment underscores how Custom Truck One Source’s current earnings outlook and perceived undervaluation may be drawing renewed investor attention. Next, we’ll examine how this value-focused Zacks coverage might influence Custom Truck One Source’s existing investment...

If you are wondering whether HubSpot's current share price reflects its true worth, you are not alone. This article will walk you through how that question can be approached using several valuation lenses. HubSpot shares last closed at US$375.96, with a 1% decline over the past week, flat returns over the last 30 days, a 1.6% decline year to date, a 46.2% decline over 1 year, a 19.1% return over 3 years, and a 2.2% decline over 5 years. Recent coverage of HubSpot has focused on its role as a...

Modine Manufacturing (MOD) is back in focus after analysts raised both current and future earnings estimates, following four straight quarters in which the company exceeded EPS and revenue forecasts and issued higher revenue expectations. See our latest analysis for Modine Manufacturing. The recent bump in earnings expectations comes after a strong multi‑year run, with Modine Manufacturing’s 1‑year total shareholder return of 7.2% sitting alongside a very large 5‑year total shareholder...

Why Qorvo (QRVO) is Back on Investor Radar Qorvo (QRVO) has been drawing fresh attention after a mixed set of return figures, with recent negative moves over the past month and past 3 months contrasting with a positive 1 year total return. See our latest analysis for Qorvo. At a share price of US$80.46, Qorvo’s recent 7 day share price return of an 8.69% decline and 30 day share price return of an 8.64% decline contrast with a 1 year total shareholder return of 10.49%. This suggests shorter...

In January 2026, Rigel Pharmaceuticals issued full-year 2026 earnings guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue. This fresh guidance gives investors a clearer view of how management currently sees the balance between core product sales and partnership-driven contract income. We’ll now consider how Rigel’s new 2026 revenue guidance,...

Viking Therapeutics (VKTX) has drawn fresh investor attention after publishing positive Phase 2 VENTURE data for its obesity candidate VK2735, along with progress in Phase 1 maintenance dosing and large Phase 3 VANQUISH trials. See our latest analysis for Viking Therapeutics. Despite the recent clinical and leadership milestones around VK2735, Viking Therapeutics’ 30 day share price return of a 14.35% decline and year to date share price return of a 10.33% decline suggest momentum has cooled,...

Royal Caribbean Cruises (RCL) just broke ground on a new US$345 million Cruise Terminal G at PortMiami, a project aimed at expanding passenger capacity and refining the embarkation experience for large ships. See our latest analysis for Royal Caribbean Cruises. The terminal groundbreaking comes as Royal Caribbean’s share price sits at US$301.13, with a 7.99% 1 month share price return and a 6.31% year to date share price return. A 1 year total shareholder return of 34.23% and very large 3 and...

Target (TGT) has put wellness front and center, rolling out a 30% expansion in its 2026 assortment. The change brings thousands of new items, exclusive brands, and refreshed in-store and digital experiences for health focused shoppers. See our latest analysis for Target. These wellness launches come as Target’s share price sits at US$106.14, with a 30 day share price return of 9.32% and 90 day share price return of 19.31%. Its 1 year total shareholder return of a 20.14% decline and 5 year...

New guidance and divided analyst opinions put HealthEquity in focus HealthEquity (HQY) is back on investors’ radar after issuing fresh revenue guidance for its fiscal year ending January 31, 2027, alongside reaffirmed expectations for the current year. The company now targets full year 2027 revenue between US$1.38b and US$1.41b, an update that arrives just as Wall Street views on the stock have moved in different directions. See our latest analysis for HealthEquity. The shares have come under...

JetBlue Airways (JBLU) shares are in focus after the airline outlined fresh route expansions in Florida and New York, including new Fort Lauderdale links and upcoming service between New York’s JFK and Cleveland. See our latest analysis for JetBlue Airways. These new routes arrive after a mixed period for investors. JetBlue’s 1-day share price return of 5.78% decline and 7-day share price return of 3.55% decline contrast with a year-to-date share price return of 6.54%. Meanwhile, the 1-year...

If you are wondering whether CommScope Holding Company is still good value after a big run in the share price, this breakdown will help you frame what the current price might be implying. The stock recently closed at US$19.04, with returns of 3.3% over 7 days, a 2.1% decline over 30 days, 4.3% year to date, 260.6% over 1 year and 109.0% over 3 years. This naturally raises questions about how much is already priced in. Recent coverage around CommScope has focused on its position in...

Chubb (CB) is back on investors’ radar after reporting quarterly revenues and earnings that topped analyst expectations, along with several recent analyst upgrades that have pushed interest in the stock higher. See our latest analysis for Chubb. At a share price of $306.62, Chubb has given investors a mixed short term experience, with recent weekly share price weakness but a 90 day share price return of 7.73% and a 1 year total shareholder return of 18.69%. This points to momentum that has...